The targets of the main compounds of XCHT are also concentrated in tumors, signal pathways, and other pathways closely related to CRC, such as Prostate cancer, IL-17 signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, NF-kappa B signaling pathway, etc. Relevant studies have shown that IL-17 inhibits CD8+ CTLs and Tregs’ infiltration by signaling in colorectal tumor cells, thereby promoting CRC development [41]. This evidence concerns the gene CD8A and prostate cancer.